Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :30024940
Publication Date : //

Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance.


Influenza viruses can cause severe life threatening infections in high-risk patients, including young children, the elderly and patients with compromised immunity due to underlying medical conditions or immunosuppressive treatment. The impaired immunity of these patients causes prolonged virus infection and combined with antiviral treatment facilitates the emergence of viruses with resistance mutations. The diverse nature of their immune status makes them a challenging group to study the impact of influenza virus infection and the efficacy of antiviral therapy. Immunocompromised ferrets may represent a suitable animal model to assess influenza virus infection and antiviral treatment strategies in immunocompromised hosts. Here, ferrets were given a daily oral solution of mycophenolate mofetil, tacrolimus and prednisolone sodium phosphate to suppress their immune system. Groups of immunocompromised and immunocompetent ferrets were inoculated with an A/H3N2 influenza virus and were subsequently treated with Oseltamivir or left untreated. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was performed on the throat and nose specimens to study virus replication during the course of infection. All immunocompromised ferrets had prolonged presence of viral RNA and a higher total amount of virus shedding compared to the immunocompetent ferrets. Although Oseltamivir reduced the total amount of virus shedding from the nose and throat of treated ferrets, it also resulted in the emergence of the neuraminidase R292K resistance substitution in all these animals, as determined by mutation specific RT-PCR and next-generation sequencing. No additional mutations that could be associated with the emergence of the R292K resistance mutation were detected. The immunocompromised ferret model can be used to study A/H3N2 virus shedding and is a promising model to study new antiviral strategies and the emergence of antiviral resistance in immunocompromised hosts.

Authors : Roosenhoff Rueshandra , van der Vries Erhard , van der Linden Anne , van Amerongen Geert , Stittelaar Koert J , Smits Saskia L , Schutten Martin , Fouchier Ron A M ,

Related products :

Catalog number Product name Quantity
orb81803 Influenza Virus H3N2 Brisbane 10_07 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Brisbane_10_07. The Influenza Virus was purified by Ultracentrifu 10
orb81802 Influenza Virus H3N2 Wisconsin 67_05 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Wisconsin_67_05. The Influenza Virus was purified by Ultracentri 10
orb81799 Influenza Virus H3N2 Shangdong 9_93 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Shandong_9_93. The Influenza Virus was purified by Ultracentrifug 10
orb81801 Influenza Virus H3N2 Panama 2007_99 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Panama_2007_99. The Influenza Virus was purified by Ultracentrifu 10
iha-011 Recombinant Hemagglutinin-Influenza A Virus H3N2 New York 55_04 VIRAL ANTIGENS- INFLUENZA VIRUS 10
iha-005 Influenza A Virus H3N2 Kiev 301_94 like _Johannesburg 33_94 VIRAL ANTIGENS- INFLUENZA VIRUS 50
iha-005 Influenza A Virus H3N2 Kiev 301_94 like _Johannesburg 33_94 VIRAL ANTIGENS- INFLUENZA VIRUS 1mg
iha-005 Influenza A Virus H3N2 Kiev 301_94 like _Johannesburg 33_94 VIRAL ANTIGENS- INFLUENZA VIRUS 10
iha-012 Recombinant Hemagglutinin-Influenza A Virus H3N2 Wyoming 3_03 VIRAL ANTIGENS- INFLUENZA VIRUS 10
iha-008 Recombinant Hemagglutinin-Influenza A Virus H3N2 Perth 16_09 VIRAL ANTIGENS- INFLUENZA VIRUS 5
iha-008 Recombinant Hemagglutinin-Influenza A Virus H3N2 Perth 16_09 VIRAL ANTIGENS- INFLUENZA VIRUS 50
iha-020 Recombinant Hemagglutinin-Influenza A Virus H3N2 Wisconsin 67_05 VIRAL ANTIGENS- INFLUENZA VIRUS 100
iha-012 Recombinant Hemagglutinin-Influenza A Virus H3N2 Wyoming 3_03 VIRAL ANTIGENS- INFLUENZA VIRUS 2
iha-011 Recombinant Hemagglutinin-Influenza A Virus H3N2 New York 55_04 VIRAL ANTIGENS- INFLUENZA VIRUS 2
iha-020 Recombinant Hemagglutinin-Influenza A Virus H3N2 Wisconsin 67_05 VIRAL ANTIGENS- INFLUENZA VIRUS 2
iha-008 Recombinant Hemagglutinin-Influenza A Virus H3N2 Perth 16_09 VIRAL ANTIGENS- INFLUENZA VIRUS 1
iha-020 Recombinant Hemagglutinin-Influenza A Virus H3N2 Wisconsin 67_05 VIRAL ANTIGENS- INFLUENZA VIRUS 10
iha-011 Recombinant Hemagglutinin-Influenza A Virus H3N2 New York 55_04 VIRAL ANTIGENS- INFLUENZA VIRUS 100
iha-012 Recombinant Hemagglutinin-Influenza A Virus H3N2 Wyoming 3_03 VIRAL ANTIGENS- INFLUENZA VIRUS 100
iha-034 Recombinant Hemagglutinin-Influenza A Virus H3N2 Canine VIRAL ANTIGENS- INFLUENZA VIRUS 5
iha-034 Recombinant Hemagglutinin-Influenza A Virus H3N2 Canine VIRAL ANTIGENS- INFLUENZA VIRUS 20
iha-034 Recombinant Hemagglutinin-Influenza A Virus H3N2 Canine VIRAL ANTIGENS- INFLUENZA VIRUS 1mg
iha-006 Influenza A Virus H3N2 Panama 2007_99 VIRAL ANTIGENS- INFLUENZA VIRUS 1mg
iha-023 Influenza A Virus H3N2 Wisconsin 67_05 VIRAL ANTIGENS- INFLUENZA VIRUS 1mg
iha-024 Influenza A Virus H3N2 Brisbane 10_07 VIRAL ANTIGENS- INFLUENZA VIRUS 1mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur